R
Rezolute, Inc. (RZLT)
NCM – Real Time Price. Currency in USD
3.30
+0.13 (4.10%)
At close: May 12, 2026, 4:00 PM EDT
3.28
-0.02 (-0.60%)
After-hours: May 12, 2026, 7:20 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
3.30
+0.13 (4.10%)
At close: May 12, 2026, 4:00 PM EDT
3.28
-0.02 (-0.60%)
After-hours: May 12, 2026, 7:20 PM EDT
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
| Name | Position |
|---|---|
| Dr. Brian Kenneth Roberts M.D. | Chief Medical Officer |
| Dr. Davelyn Eaves Hood M.B.A., M.D. | Director and Head of Scientific & Patient Affairs |
| Dr. Raj Agrawal M.D. | VP & Head of Ophthalmological Clinical Development |
| Mr. Chris Milks | VP & Head of Finance |
| Mr. Daron G. Evans M.B.A., M.S. | Chief Financial & Business Officer |
| Mr. Michael Covarrubias | Senior VP & Head of Program & Portfolio Management |
| Date | Type | Document |
|---|---|---|
| 2026-05-12 | 10-Q | rzlt-20260331x10q.htm |
| 2026-05-04 | 8-K | tm2613408d1_8k.htm |
| 2026-03-24 | 8-K | tm269642d1_8k.htm |
| 2026-02-12 | 10-Q | rzlt-20251231x10q.htm |
| 2026-01-07 | 8-K | tm262357d1_8k.htm |
| 2025-12-05 | S-3ASR | tm2532714-1_s3asr.htm |
| 2025-11-21 | 8-K | tm2531775d2_8k.htm |
| 2025-11-12 | 8-K | tm2530840d1_8k.htm |
| 2025-11-06 | 8-K | tm2529989d1_8k.htm |
| 2025-10-21 | 8-K | tm2529201d1_8k.htm |
| Mr. Michael R. Deperro | Senior VP & Head of Operations |
| Mr. Nevan Charles Elam J.D. | Founder, CEO, Principal Financial Officer & Acting Chairman of the Board |
| Ms. Melissa Quinn | Senior Director of People and Culture |
| Ms. Robyn Sweinhart | VP & Head of Quality |